| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple sclerosis | 4 | 0 | |
| Growths or tumors (dysplasia) | 1 | 1 | |
| Lupus nephritis | 1 | 0 | |
| Scleroderma | 1 | 0 | |
| Systemic lupus erythematosus | 1 | 1 |
Side effect severity
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 1 | |
| Moderate | 0 | |
| Mild | 0 | |
| None | 0 |